{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T07:46:08Z","timestamp":1769586368511,"version":"3.49.0"},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2014,5,16]],"date-time":"2014-05-16T00:00:00Z","timestamp":1400198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Novartis Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The approval of multiple tyrosine kinase inhibitors targeting <jats:styled-content style=\"fixed-case\">BCR<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">ABL<\/jats:styled-content> has broadened the number of available therapeutic options for chronic myeloid leukemia in the chronic phase (<jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CP<\/jats:styled-content>). This provides an impetus for optimizing prognostic risk score systems that can guide treatment decisions. Presently, three risk scores\u2014the Sokal, Hasford, and European Treatment and Outcome Study (<jats:styled-content style=\"fixed-case\">EUTOS<\/jats:styled-content>) metrics\u2014have been implemented clinically in <jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CP<\/jats:styled-content>. While these three formulations all endeavor to gauge likely disease course, they differ from one another in several important respects, with potential implications for prognosis and therapy. Here, we review these risk scores and propose how prognostic systems in <jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CP<\/jats:styled-content> might be refined to direct patients to optimally effective therapies as efficiently and accurately as possible.<\/jats:p>","DOI":"10.1111\/ejh.12356","type":"journal-article","created":{"date-parts":[[2014,4,26]],"date-time":"2014-04-26T15:34:00Z","timestamp":1398526440000},"page":"179-186","source":"Crossref","is-referenced-by-count":14,"title":["Impact of risk score calculations in choosing front\u2010line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase"],"prefix":"10.1111","volume":"93","author":[{"given":"Bei","family":"Hu","sequence":"first","affiliation":[{"name":"Hematology and Stem Cell Transplantation Section Division of Hematology\/Oncology Department of Medicine Vanderbilt University Medical Center and Veterans Affairs Medical Center Nashville TN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation Section Division of Hematology\/Oncology Department of Medicine Vanderbilt University Medical Center and Veterans Affairs Medical Center Nashville TN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,5,16]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3460176"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441402"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055104"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.7522"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306494"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2922"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-065599"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.4.789.789"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.11.850"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-319038"},{"key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1182\/blood.V118.21.2759.2759","article-title":"A phase IIIb multicentre open\u2010label study of nilotinib in adult patients with newly diagnosed BCR\u2010ABL positive chronic myeloid leukemia (CML) in chronic phase (CP): a European clinical initiative with EUTOS collaboration for standardisation of molecular remission","volume":"118","author":"Giles FJ","year":"2011","journal-title":"Blood"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.6962"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92596-1"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.012781"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02366.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-388967"},{"key":"e_1_2_8_22_1","doi-asserted-by":"crossref","first-page":"Abstract 3759","DOI":"10.1182\/blood.V120.21.3759.3759","article-title":"EUTOS score is also valid in CML patients not involved in clinical studies","volume":"120","author":"Hoffmann VS","year":"2012","journal-title":"Blood"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.171"},{"key":"e_1_2_8_24_1","doi-asserted-by":"crossref","first-page":"Abstract 3778","DOI":"10.1182\/blood.V120.21.3778.3778","article-title":"EUTOS score identifies cases with poor outcome in patients with early chronic phase chronic myeloid leukemia, though not predictive for optimal response to imatinib","volume":"120","author":"Tiribelli M","year":"2012","journal-title":"Blood"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-402511"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.05.011"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1179\/1607845412Y.0000000071"},{"key":"e_1_2_8_28_1","doi-asserted-by":"crossref","first-page":"Abstract 2794","DOI":"10.1182\/blood.V120.21.2794.2794","article-title":"Comparison of Sokal, Hasford and EUTOS scores in terms of long\u2010term treatment outcome according to the risks in each prognostic model: a single center data analyzed in 255 early chronic phase chronic myeloid leukemia patients treated with frontline imatinib mesylate","volume":"120","author":"Yahng SA","year":"2012","journal-title":"Blood"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483750"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0055"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12356","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12356","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.12356","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T07:33:51Z","timestamp":1696318431000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,16]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1111\/ejh.12356"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12356","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,16]]}}}